SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis

• Published in: International journal of biological sciences 2021-01, Vol.17 (11), p.2912-2930
• Main Authors: Li, Hao, Wang, Di, Yi, Bolong, Cai, Heng, Wang, Yipeng, Lou, Xin, Xi, Zhuo, Li, Zhen
• Format: Article
• Language: English
• Subjects: 3' Untranslated regions; Angiogenesis; Animals; Antiangiogenics; Antibodies; Apoptosis; Assaying; Binding; Brain cancer; Brain tumors; Breast cancer; Cell culture; Cell growth; Cell Line, Tumor; Cell Proliferation - genetics; Central nervous system; Cholecystokinin; Enzymes; Gene expression; Gene Expression Regulation, Neoplastic; Glioma - genetics; Glioma - metabolism; Glioma - pathology; Glioma cells; Humans; Immunofluorescence; Immunoprecipitation; Localization; Lung cancer; Lysine; Medical prognosis; Mice; Mice, Nude; MicroRNAs - genetics; MicroRNAs - metabolism; Mimicry; mRNA; Nervous system; Pancreatic cancer; Polymerase chain reaction; Post-translation; Proteasomes; Proteins; Research Paper; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; RNA-Binding Proteins - genetics; RNA-Binding Proteins - metabolism; Stability; Substrates; SUMO protein; Sumoylation; Therapy; Tumorigenesis; Tumorigenicity; Tumors; Ubiquitin; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation
• ISSN: 1449-2288; 1449-2288
• DOI: 10.7150/ijbs.58035

Glioma is the most common primary malignant tumor of human central nervous system, and its rich vascular characteristics make anti-angiogenic therapy become a therapeutic hotspot. However, the existence of glioma VM makes the anti-angiogenic therapy ineffective. SUMOylation is a post-translational modification that affects cell tumorigenicity by regulating the expression and activity of substrate proteins. The binding and modification of IGF2BP2 and SUMO1 were identified using Ni -NTA agarose bead pull-down assays, CO-IP and western blot; and in vitro SUMOylation assays combined with immunoprecipitation and immunofluorescence staining were performed to explore the detail affects and regulations of the SUMOylation on IGF2BP2. RT-PCR and western blot were used to detect the expression levels of IGF2BP2, OIP5-AS1, and miR-495-3p in glioma tissues and cell lines. CCK-8 assays, cell transwell assays, and three-dimensional cell culture methods were used for evaluating the function of IGF2BP2, OIP5-AS1, miR-495-3p, HIF1A and MMP14 in biological behaviors of glioma cells. Meantime, RIP and luciferase reporter assays were used for inquiring into the interactions among IGF2BP2, OIP5-AS1, miR-495-3p, HIF1A and MMP14. Eventually, the tumor xenografts in nude mice further as certained the effects of IGF2BP2 SUMOylation on glioma cells. This study proved that IGF2BP2 mainly binds to SUMO1 and was SUMOylated at the lysine residues K497, K505 and K509 sites, which can be reduced by SENP1. SUMOylation increased IGF2BP2 protein expression and blocked its degradation through ubiquitin-proteasome pathway, thereby increasing its stability. The expressions of IGF2BP2 and OIP5-AS1 were up-regulated and the expression of miR-495-3p was down-regulated in both glioma tissues and cells. IGF2BP2 enhances the stability of OIP5-AS1, thereby increasing the binding of OIP5-AS1 to miR-495-3p, weakening the binding of miR-495-3p to the 3'UTR of HIF1A and MMP14 mRNA, and ultimately promoting the formation of VM in glioma. This study first revealed that SUMOylation of IGF2BP2 regulated OIP5-AS1/miR-495-3p axis to promote VM formation in glioma cells and xenografts growth in nude mice, providing a new idea for molecular targeted therapy of glioma.